JP2012046483A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012046483A5 JP2012046483A5 JP2011126449A JP2011126449A JP2012046483A5 JP 2012046483 A5 JP2012046483 A5 JP 2012046483A5 JP 2011126449 A JP2011126449 A JP 2011126449A JP 2011126449 A JP2011126449 A JP 2011126449A JP 2012046483 A5 JP2012046483 A5 JP 2012046483A5
- Authority
- JP
- Japan
- Prior art keywords
- testosterone
- androgen
- composition
- serum
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 48
- 229960003604 testosterone Drugs 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 18
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 239000003098 androgen Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- -1 testosterone ester Chemical class 0.000 claims 2
- 150000003515 testosterones Chemical class 0.000 claims 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims 1
- 229960003473 androstanolone Drugs 0.000 claims 1
- 229960005471 androstenedione Drugs 0.000 claims 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001566 methyltestosterone Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000035946 sexual desire Effects 0.000 claims 1
- 229960000921 testosterone cypionate Drugs 0.000 claims 1
- HPFVBGJFAYZEBE-ZLQWOROUSA-N testosterone cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)CC[C@@]21C)C(=O)CCC1CCCC1 HPFVBGJFAYZEBE-ZLQWOROUSA-N 0.000 claims 1
- 229960003484 testosterone enanthate Drugs 0.000 claims 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/464,310 US20040259852A1 (en) | 2003-06-18 | 2003-06-18 | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| US10/464,310 | 2003-06-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517316A Division JP5717312B2 (ja) | 2003-06-18 | 2004-06-15 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012046483A JP2012046483A (ja) | 2012-03-08 |
| JP2012046483A5 true JP2012046483A5 (https=) | 2012-08-30 |
| JP5651540B2 JP5651540B2 (ja) | 2015-01-14 |
Family
ID=33517268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517316A Expired - Fee Related JP5717312B2 (ja) | 2003-06-18 | 2004-06-15 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
| JP2011126449A Expired - Fee Related JP5651540B2 (ja) | 2003-06-18 | 2011-06-06 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517316A Expired - Fee Related JP5717312B2 (ja) | 2003-06-18 | 2004-06-15 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20040259852A1 (https=) |
| EP (2) | EP2000143B1 (https=) |
| JP (2) | JP5717312B2 (https=) |
| AU (2) | AU2004251075B2 (https=) |
| CA (1) | CA2529575C (https=) |
| WO (1) | WO2005000236A2 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2255599C (en) | 1996-04-25 | 2006-09-05 | Bioarray Solutions, Llc | Light-controlled electrokinetic assembly of particles near surfaces |
| US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
| US7262063B2 (en) | 2001-06-21 | 2007-08-28 | Bio Array Solutions, Ltd. | Directed assembly of functional heterostructures |
| CA2497740C (en) | 2001-10-15 | 2011-06-21 | Bioarray Solutions, Ltd. | Multiplexed analysis of polymorphic loci by probe elongation-mediated detection |
| AU2003298655A1 (en) | 2002-11-15 | 2004-06-15 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
| US9511079B2 (en) | 2003-06-18 | 2016-12-06 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| CA2539824C (en) | 2003-09-22 | 2015-02-03 | Xinwen Wang | Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules |
| CA2544041C (en) | 2003-10-28 | 2015-12-08 | Bioarray Solutions Ltd. | Optimization of gene expression analysis using immobilized capture probes |
| ATE319426T1 (de) | 2003-11-11 | 2006-03-15 | Mattern Udo | Nasenformulierung mit kontrollierter freisetzung von sexualhormonen |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| EP1750766B1 (en) | 2004-05-11 | 2013-07-03 | Emotional Brain B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| US7848889B2 (en) | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| CA2664427C (en) | 2006-10-04 | 2012-06-05 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| CA2643529C (en) * | 2008-11-06 | 2019-05-21 | Kenneth W. Adams | Method and composition for enhancement of male erectile function |
| EP2640398A4 (en) * | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US20240293322A1 (en) | 2021-06-23 | 2024-09-05 | University Of Iowa Research Foundation | Sustained release formulations comprising a selective androgen receptor modulator |
| CA3255973A1 (en) * | 2022-07-29 | 2024-02-01 | University Of Rochester | METHODS FOR IMPROVING MUSCLE MASS, STRENGTH, OR FUNCTION WITH A COMBINATION OF TESTOSTERONE AND GROWTH HORMONE |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4542129A (en) * | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
| US5019395A (en) | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
| US5461042A (en) | 1988-12-30 | 1995-10-24 | Loria; Roger M. | Regulation of the immune system |
| US5206008A (en) | 1991-04-15 | 1993-04-27 | Virginia Commonwealth University | Enhancement of immune response |
| US5676968A (en) | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
| US5656606A (en) * | 1995-02-17 | 1997-08-12 | Merck & Co., Inc. | Camphor compounds promote release of growth hormone |
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
| DE19619045C1 (de) | 1996-05-02 | 1997-11-13 | Jenapharm Gmbh | Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen |
| US5709878A (en) | 1996-08-02 | 1998-01-20 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US5855920A (en) | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| DE19701949A1 (de) | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
| AU6265998A (en) * | 1997-02-07 | 1998-08-26 | Theratech, Inc. | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
| US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| HUP0001748A3 (en) | 1997-02-28 | 2001-03-28 | Minnesota Mining And Mfg Co Sa | Transdermal device for the delivery of testosterone |
| US5968919A (en) | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| JP4139860B2 (ja) | 1997-11-10 | 2008-08-27 | ストラカン インターナショナル リミティッド | 浸透増強および刺激減少システム |
| US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US5935949A (en) * | 1998-03-20 | 1999-08-10 | Trustees Of Dartmouth College | Use of androgen therapy in fibromyalgia and chronic fatigue syndrome |
| US6165504A (en) * | 1998-09-23 | 2000-12-26 | Barr Laboratories, Inc. | Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients |
| FR2801507B1 (fr) | 1999-11-30 | 2003-06-27 | Pf Medicament | Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations |
| ATE310728T1 (de) * | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| US8980290B2 (en) * | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| ATE485837T1 (de) | 2000-08-03 | 2010-11-15 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| AU2001285367B2 (en) * | 2000-08-30 | 2006-05-18 | Besins Healthcare Luxembourg Sarl | Method of increasing testosterone and related steroid concentrations in women |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| ES2341090T3 (es) | 2000-08-30 | 2010-06-15 | Unimed Pharmaceuticals, Llc | Procedimiento para tratar la disfuncion erectil y aumentar la libido en hombres. |
| US6573258B2 (en) * | 2000-09-27 | 2003-06-03 | Frontier Scientific, Inc. | Photodynamic porphyrin antimicrobial agents |
| WO2002055020A2 (en) | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
| CA2446060A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030175329A1 (en) | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
| US6980852B2 (en) | 2002-01-25 | 2005-12-27 | Subqiview Inc. | Film barrier dressing for intravascular tissue monitoring system |
| US7049313B2 (en) * | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
| HU230920B1 (hu) | 2002-03-15 | 2019-03-28 | Besins Healthcare Luxembourg Sarl | Depresszió kezelésére szolgáló androgén gyógyászati készítmények |
| IL163981A0 (en) | 2002-03-15 | 2005-12-18 | Unimed Pharmaceuticals Inc | Androgen pharmaceutical composition and method fortreating depression |
| MY139721A (en) | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US20040259784A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Compositions and methods for treatment of muscle pain and muscle wasting |
| US20050025833A1 (en) | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US20050042268A1 (en) | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US20050020552A1 (en) | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| ATE534373T1 (de) * | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| WO2006102476A2 (en) * | 2005-03-21 | 2006-09-28 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
| EP1868437A4 (en) * | 2005-04-12 | 2009-08-05 | Unimed Pharmaceuticals Inc | METHOD FOR TREATING OR PREVENTING BONE REMOVAL OR OSTEOPOROSIS |
| EP1868590A4 (en) | 2005-04-13 | 2012-08-29 | Unimed Pharmaceuticals Inc | PROCESS FOR INCREASING TESTOSTERONE AND CORRESPONDING STEROID CONCENTRATIONS IN WOMEN |
| CA2604943C (en) | 2005-04-15 | 2013-09-17 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| US8492369B2 (en) * | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| KR20130114229A (ko) | 2005-06-03 | 2013-10-16 | 애크럭스 디디에스 피티와이 리미티드 | 경피 약물 전달 방법 및 조성물 |
| US20080261937A1 (en) * | 2007-03-23 | 2008-10-23 | Dudley Robert E | Pharmaceutical compositions and method for treating pediatric hypogonadism |
| EP2640398A4 (en) * | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF |
-
2003
- 2003-06-18 US US10/464,310 patent/US20040259852A1/en not_active Abandoned
-
2004
- 2004-06-15 JP JP2006517316A patent/JP5717312B2/ja not_active Expired - Fee Related
- 2004-06-15 EP EP08154166.6A patent/EP2000143B1/en not_active Expired - Lifetime
- 2004-06-15 AU AU2004251075A patent/AU2004251075B2/en not_active Ceased
- 2004-06-15 CA CA2529575A patent/CA2529575C/en not_active Expired - Fee Related
- 2004-06-15 EP EP04776655A patent/EP1638575A4/en not_active Withdrawn
- 2004-06-15 WO PCT/US2004/019201 patent/WO2005000236A2/en not_active Ceased
-
2005
- 2005-12-16 US US11/303,813 patent/US7799769B2/en not_active Expired - Fee Related
-
2010
- 2010-07-15 US US12/837,310 patent/US8999963B2/en not_active Expired - Fee Related
-
2011
- 2011-03-02 AU AU2011200914A patent/AU2011200914B2/en not_active Ceased
- 2011-06-06 JP JP2011126449A patent/JP5651540B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012046483A5 (https=) | ||
| EP2667851B1 (en) | Testosterone formulations | |
| JP2014528474A5 (https=) | ||
| JP5897592B2 (ja) | 葉酸−ラミプリルの組合せ：細胞保護性、神経保護性、および網膜保護性の眼科用組成物 | |
| KR20030048021A (ko) | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 | |
| KR20080016552A (ko) | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 | |
| TW201309302A (zh) | 治療眼部病症之雄性激素組合物 | |
| CA2957548A1 (en) | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof | |
| JP2016539921A5 (https=) | ||
| WO2011129461A1 (en) | Method and ophthalmic composition for treating retinal disease | |
| JP2020500864A5 (https=) | ||
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| AU2017357755B2 (en) | Formulations for the treatment of ocular surface diseases and related methods | |
| WO2010075315A2 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| JP2015523986A5 (https=) | ||
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| JP2017522389A (ja) | シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療 | |
| JP2016537364A5 (https=) | ||
| EP3727382A1 (en) | Compositions and methods for preventing and treating conditions | |
| JP2021059539A (ja) | 排尿障害改善剤 | |
| JP2021508523A (ja) | 経皮薬物送達システムおよびその使用方法 | |
| JP2014505074A5 (https=) | ||
| US20230128304A1 (en) | Benzimidazole compound for the treatment of metabolic disorders | |
| US10438128B2 (en) | Treatment of autoimmune and inflammatory diseases with the arsenic compounds AS2O3 and/or AS2O5 administered locally | |
| JP2016503406A5 (https=) |